The transaction is expected to close in the fourth quarter of 2022, subject to receipt of requisite approval by PZN stockholders and satisfaction of other customary closing conditions.
The merger agreement was unanimously approved by a Special Committee of independent and disinterested directors following careful consideration and a robust negotiation process. The Committee concluded that the transaction is in the best interest of holders of PZN’s Class A common stock. Acting upon the Special Committee’s recommendation, the Board of Directors of PZN approved the transaction.
The Board of Directors recommends that stockholders vote FOR the adoption of the merger agreement and the other proposals described in the proxy statement, pursuant to which Pzena will become a private company and holders of PZN Class A common stock will receive
Important Information for Investors
The record date for the special meeting is
In the definitive proxy, investors can find instructions on how to join the webcast and voting procedures. There are a number of ways to vote and it is important that investors understand their options. Whether or not investors attend the special meeting, the Special Committee recommend voting “FOR” the Merger Agreement Proposal, “FOR” the Adjournment Proposal and “FOR” the Merger-Related Compensation Proposal. If stockholders need assistance in voting their shares, they should reach out to
Forward-looking Statements
Certain statements and information contained in this press release may be considered “forward-looking statements,” such as statements relating to management’s views with respect to future events and financial performance. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, economic conditions in the markets in which PZN operates; new federal or state governmental regulation; PZN’s ability to effectively operate, integrate and leverage any past or future strategic initiatives; statements regarding the merger and related matters; the ability to meet expectations regarding the timing and completion of the merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the failure to obtain PZN stockholder approval of the transaction or the failure to satisfy any of the other conditions to the completion of the transaction; risks relating to the financing required to complete the transaction; the effect of the announcement of the transaction on the ability of PZN to retain and hire key personnel and maintain relationships with its customers, vendors and others with whom it does business, or on its operating results and businesses generally; risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; significant transaction costs, fees, expenses and charges; the risk of litigation and/or regulatory actions related to the transaction; and other factors detailed in PZN’s Annual Report on Form 10-K filed with the
Additional Information and Where to Find It
In connection with the proposed merger transaction, PZN has filed with the
Investors will be able to obtain a free copy of documents filed with the
Participants in the Solicitation
PZN, its directors and certain of its officers and employees, may be deemed to be participants in the solicitation of proxies from PZN stockholders in connection with the proposed transaction. Information about the Company’s directors and executive officers is set forth in its definitive proxy statement for its 2022 annual meeting of shareholders filed with the
Contact
Source:
2022 GlobeNewswire, Inc., source